title: Clinicopathologic and molecular features of Hodgkin's lymphoma.
abstract: Hodgkin's lymphoma is a relatively uncommon malignancy that predominantly effects young adults. It became the first human cancer to be cured with combination chemotherapy. Unfortunately, many cured patients do not live their expected lifespan because of long-term lethal effects of therapy. Novel treatment strategies based on our understanding of Hodgkin's lymphoma biology are currently being explored to maintain the high cure rate without the added treatment related toxicity.
authors: Department of Lymphoma/Myeloma, MD Anderson Cancer Center, Houston, Texas 77030, USA. ayounes@mdanderson.org
authors: Anas
authors: A
authors: Younes
authors: Antonio
authors: A
authors: Carbone
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001761:Bleomycin / Q000627:therapeutic use; D003131:Combined Modality Therapy; D003606:Dacarbazine / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D005260:Female; D006689:Hodgkin Disease / Q000235:genetics* / Q000473:pathology* / Q000628:therapy; D006801:Humans; D008207:Lymphatic Metastasis; D018714:Radiotherapy, Adjuvant; D012074:Remission Induction; D033581:Stem Cell Transplantation; D014747:Vinblastine / Q000627:therapeutic use
chemical_list: D001761:Bleomycin; D014747:Vinblastine; D003606:Dacarbazine; D004317:Doxorubicin